ReviewCurrent cardiology reports2026
Impact of Fixed-Dose Combination Therapies on Cardiovascular Mortality and Major Cardiovascular Events.
Review in Current cardiology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewFixed-dose combination therapy (the polypill) was developed to reduce treatment complexity and improve adherence to evidence-based cardiovascular therapies. This review evaluates contemporary evidence for its effects on major cardiovascular events and cardiovascular mortality across primary prevention, secondary prevention, and emerging heart failure applications, while addressing implementation barriers and remaining evidence gaps. RECENT
findingsEarly pharmacodynamic and adherence trials established that co-formulation preserves the effects of individual components and improves medication adherence. Event-powered trials subsequently demonstrated clinical benefit: PolyIran and TIPS-3 reduced major cardiovascular events in predominantly primary prevention population, whereas SECURE reduced recurrent events after myocardial infarction. Individual-participant and aggregate-data meta-analyses showed relative reductions of approximately 20% to 40% in composite cardiovascular outcomes and a reduction in cardiovascular mortality, with larger benefits among patients with greater adherence and in aspirin-containing strategies. POLY-HF extended the approach to heart failure with reduced ejection fraction, improving left ventricular ejection fraction and uptake of guideline-directed therapy; reductions in heart failure events were secondary findings that require confirmation in larger outcome trials. These findings supports fixed-dose combination therapy as an effective strategy for improving adherence and reducing cardiovascular events, with a cardiovascular mortality benefit supported by pooled analyses. Its greatest potential may be in high-risk populations and resource-limited settings, where treatment complexity impedes implementation. Broader adoption will require formulation standardization, sufficient dosing flexibility, longer-term safety data, and effective integration into clinical guidelines and health systems.
Indexed as
Identifiers
42900438What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.